In summary, we identified MAGEA3 and ANGPT2 as potential biomarkers for predicting bevacizumab efficacy in CRC, with MAGEA3 showing the most significant correlation with patient survival. This evidence concerns the gene MAGEA3 and colorectal carcinoma.